Adventurer Pro 2100g x 0.1g Offered for Sale at Block Scientific

Block Scientific offers OHAUS’ high-precision Adventurer Pro 2100g x 0.1g balance that delivers traceable results.

You can now purchase the versatile Adventurer Pro 2100g x 0.1g balance from Block Scientific, a leading laboratory equipment supplier based in New York, offering a wide range of new and recertified equipment. One of the popular models of precision balances in the Adventurer Pro line from OHAUS, the Adventurer Pro 2100g x 0.1g has established itself as the industry’s most versatile balance. It counts, it sums, it holds and it delivers traceable results.

Adventurer Pro 2100g x 0.1g offers the following features in a compact design.

  • Easy access, frameless draftshield with removable doors
  • SmarText™ software guides users through balance use
  • QuadraStance™ design provides superior footprint stability

SmarText™ is OHAUS’ easy to use balance software that utilizes text prompts to guide users through application use and balance setup. This model ensures weighing accuracy with InCal™ internal calibration. USB or second RS232 interface option allows connection to multiple peripherals.

About Block Scientific

laboratory equipment supplier based inNew York, offering a comprehensive range of lab equipment and supplies that cater to your exact needs. We carry equipment such as blood gas analyzers, electrolyte analyzers, chemistry analyzers, immunology analyzers, hematology analyzers, coagulation analyzers, and much more.  Apart from the new models, we offer recertified lab products that meet manufacturer’s specifications.

For more information, visit www.blockscientificstore.com or contact:

1620 Ocean Avenue
Unit 3
Bohemia, NY 11716 USA
Tel : 1-866-203-5777 (toll free)
Tel : 631-589-1118
Fax : 631-589-4088

E-mail – info@blockscientific.com

Earnings In Nursing

In case you were to ballot nursing students enrolled in affiliate degree packages in the nation’s group schools, you’ll discover that a good proportion of them are persuing second or third careers. Former business majors, accountants, lecturers, social employees, bankers and engineers could be found finding out to take a seat for the state boards in Professional Nursing. One of the reasons nursing is chosen for a career are the wages.

For highschool seniors trying to find a career, nursing is wise choice. The place else can an 18 yr previous go for two years to a fairly priced community college, and come out with the earning capability to gross up to$seventy five,000 for a workers nurse, in accordance with Monster.com. Wages differ from state to state and even inside communities. Nurses working for a union organized city health heart affiliated with a university could make more money than a small non-public community hospital in the identical area.

Wages are generally paid to workers nurses on an hourly basis. A staff nurse is is an expert nurse who supervises the tasks carried out by Licensed Practical Nurses, orderlies and nursing assistants. They provide direct nursing care and make selections regarding plans of care for patients based on therapy orders written by the affected person’s physician. Most hospitals designate broad perameters inside which the nurse operates. Workers nurses want a huge info base to care for the numerous needs of her patients.

Clinical specialists and superior observe nurses are paid increased wages based on their advanced education and elevated responsibility. Within the Northeastern United States, APN’s might make as much as $ninety,000. Certified registered nurse anesthetist (CRNA) may make up to $120,000 base pay. CNS, APN, and CRNA are all grasp prepared.

Along with increased wages for nurses, the excessive stress nature of the job requires extra time off than jobs with much less stress. Trip, personal days and sick time add as much as 50 – 60 days in some Northeastern US hospitals.

American Lung Association Applauds Move By CMS To Cover Tobacco Cessation Services By Phone Under Medicaid Program

Main Category: Smoking / Quit Smoking
Also Included In: Medicare / Medicaid / SCHIP
Article Date: 27 Jun 2011 – 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

Paul G. Billings, American Lung Association Vice President of National Policy and Advocacy, issued the following statement in response to the U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services’ announcement to partially reimburse state quitlines for tobacco cessation services provided by phone to Medicaid recipients:

“The American Lung Association is very pleased with today’s decision by the Centers for Medicare and Medicaid Services to allow state Medicaid programs to cover telephone counseling to help smokers quit, also known as quitlines. This will make it easier for states to provide evidence-based treatments to people on Medicaid who smoke. This is absolutely crucial because the smoking rate among Medicaid recipients is more than 60 percent higher than the rate in the general population.

“This important decision comes on the heels of the announcement by the U.S. Food and Drug Administration earlier this week of the new graphic warning labels that will appear on cigarette packs starting in fall 2012. The 1-800-QUIT-NOW number that connects to every state’s quitline will appear on those new cigarette package warning labels, so this announcement is very timely. It is now essential for states to take action, and include tobacco cessation services by phone in their state Medicaid plans. Telephone counseling is an important element of comprehensive tobacco cessation coverage, which also includes group and individual counseling, and medications to help smokers quit.”

Source:

American Lung Association




Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Smoking / Quit Smoking headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.

Electrosurgical Generator Options

Origins of electrosurgery
Did you know that development of the first commercial electrosurgical device is credited to Dr. William T. Bovie, who worked on it from 1914 to 1927 at Harvard University?  The first use of an electrosurgical generator in operating room occurred on October 1, 1926 in a surgery performed by Dr. Harvey Cushing.

The low-powered hyfrecator, manufactured by the Birtcher Corporation of Los Angeles, for electrosurgery performed on conscious patients in an office setting was in 1940.  The word Hyfrecator® is a brand name derived from “high-frequency eradicator.”  However, a number of manufacturers now produce Hyfrecators and the term, with a lower-case “h,” has since come to be used generically to refer to any dedicated non-ground-return electrosurgical apparatus.

Ganim Medical’s pre-owned and refurbished electrosurgical units
At Ganim Medical, we offer pre-owned and refurbished medical equipment that permits healthcare facilities to use the latest technology for patient treatment, without breaking the bank.  Refurbished medical equipment can be the answer to your needs, instead of making large capital investments in new devices that can become quickly outdated.  Our electrosurgical units come refurbished, rebuilt, and repainted, and include a standard 90-day warranty.

Conmed Excalibur Plus PC Electrosurgical Unit (Pre-Owned) $2,900
This device features the powerful isolated ESU available, allowing the Surgeon to adjust power settings from the surgical field with a standard ES pencil.  The Excalibur Plus PC-patented controlled output voltage in CUT maintains minimum necessary voltage for smooth cutting through various impedance tissues with minimal thermal damage.  This electrosurgical generator includes cut, coag, bipolar and blend.

Conmed Hyfrecator 2000 Electrosurgical Unit (Pre-Owned) $700
Features include a memory to store up to three power settings.  The remote-control, hand- switching pencil can change power settings while maintaining the sterile field and decreasing procedure time.  The dual microprocessors permit (1) controlling the function and output of the hyfrecator, (2) termination activation if a hazard or safety issue is detected.  This device is a cost-effective alternative to various laser procedures.

Conmed Sabre 2400 Electrosurgical Unit (Pre-Owned/Refurbished) $1,800
This high-power electrosurgical unit has a monopolar foot pedal.  The unit is designed to accommodate the needs of all surgical procedures.  It features independent monopolar outputs, enhanced bipolar performance, and can be programmed for standardization.  It also combines automatic feedback circuitry and visual displays to provide the most sensitive contact quality monitoring system available today.

ValleyLab Force 2 Electrosurgical Unit (Pre-Owned/Refurbished) $3,900
The ValleyLab Force 2 electrosurgical generator provides cutting and coagulation in monopolar or bipolar outputs.  The unit offers high-performance capabilities in a multipurpose generator, while featuring flexibility through varying degrees of homeostasis.  The operator can choose one of three preset modes: simultaneous independent coagulation, low-voltage coagulation, and Valleylab REM™ safety, which substantially reduce the risk of patient burns at the return electrode site.

For more information on any of these electrosurgical generators, see our web site or call 800-522-5909.

State Smoking Cessation Quitlines May Be Reimbursed For Medicaid Patients Working To Quit

Main Category: Medicare / Medicaid / SCHIP
Also Included In: Smoking / Quit Smoking
Article Date: 25 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Patient / Public:not yet rated

Healthcare Prof:not yet rated

Today the U.S. Center for Medicare and Medicaid (CMS) announced historic new expanded coverage options that States may offer for tobacco cessation services. This means Americans could now have more tools from their state and local tobacco control programs for help to tackle and overcome smoking and addiction to nicotine. This announcement is a major step towards reducing the tobacco epidemic in the U.S., which kills more than 400,000 people each year. These premature deaths are entirely preventable, and now states will have more resources through Medicaid to do just that.

In 2007, Legacy® published a report, Saving Lives, Saving Money II, referenced by CMS in today’s announcement, that showed that Medicaid could reap huge cost savings by funding effective tobacco prevention and cessation programs. These programs could cut Medicaid costs by 5.6 percent (spending nearly $10 billion less)if all Medicaid beneficiaries who smoke, quit.

Smokers who receive recommended counseling and who take recommended quit-smoking medications are more likely to quit and stay quit. Therefore, the announcement this week by the U.S. Food and Drug Administration that new graphic warning labels will also feature the toll-free 1-800-QUIT-NOW number on cigarette packs has been widely applauded . However, the states have made ‘penny wise pound foolish’ cuts that undercut the public health infrastructure needed as smokers reach out for help. By expanding coverage for tobacco cessation under the Affordable Care Act, state quitlines will be better prepared to respond to the onslaught of calls and smokers can get the help they desperately need.

Source: Legacy




Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Medicare / Medicaid / SCHIP headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.

Health Economics Model Shows That Dermagraft® Combined With Conventional Care Is A Cost-Effective Treatment For Diabetic Foot Ulcers In Medicare

Main Category: Diabetes
Also Included In: Medicare / Medicaid / SCHIP
Article Date: 25 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Advertisement

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Advanced BioHealing, Inc. (ABH), a leader in commercializing living cell-therapies, a cornerstone technology in the field of regenerative medicine, today announced results from a health economics model developed by The Lewin Group (Falls Church, VA) that showed the addition of Dermagraft® to conventional care for the treatment of chronic diabetic foot ulcers (DFUs) resulted in a significant therapeutic and cost benefit compared to conventional care alone in both Medicare and commercially insured populations.

Results demonstrated that additional costs for Dermagraft were offset by medical savings from accelerated wound healing and reduced DFU complications and amputations. Significantly more DFUs were healed using Dermagraft plus conventional care compared to conventional care alone. The model also found that patients receiving Dermagraft were predicted to have fewer ulcer-related amputations and bone resections at 52 weeks than those receiving conventional care alone and that Dermagraft plus conventional care provided a significant reduction in the 52-week cost of care for patients with DFUs, as compared to conventional care alone.

“Diabetes and associated complications, like DFUs, place a significant economic burden on the U.S. healthcare system, with Medicare spending 32 percent of its total budget on beneficiaries with diabetes,” said Dean Tozer, Senior Vice President of ABH. “The data provides an example of how advanced therapies, like Dermagraft, can be cost-effective for the Medicare system, and has the potential to change the entire discussion around how advanced therapies can be part of the solution to reducing future costs of Medicare.”

Results from the model (abstract number: 0053-LB) will be presented at the American Diabetes Association 71st Scientific Sessions during the General Poster Session II on Sunday, June 26, 2011 from 12:00 to 2:00 p.m. PDT at the San Diego Convention Center in Hall B.

Model Results

In the model, the proportion of healed ulcers was 76% in the Dermagraft plus conventional care arm versus 50% in conventional care alone. Median time to heal was 19-20 weeks for patients receiving Dermagraft compared to 51-52 weeks for those receiving conventional care alone. Additionally, patients receiving Dermagraft had fewer infections and amputations.

The average expected cost to Medicare per treated patient over 52 weeks was $23,080 for patients receiving Dermagraft compared to $28,505 for those receiving conventional care alone. The average estimated cost per healed ulcer (i.e. costs associated with the treatment of the ulcers that completely healed) was $30,344 in the Dermagraft plus conventional care arm compared to $56,516 for conventional care alone. Cost neutrality for Dermagraft was achieved at 6 months for Medicare payers and 8 months for private insurers. When using commercial reimbursement rates, Dermagraft provided similar but smaller cost effective ratios. Cost results are given in 2009 U.S. dollars.

About the Model

A Markov model was created that incorporated both clinical data from a pivotal, randomized, controlled study and U.S. cost and resource data from Medicare and private insurers claims databases to provide a cost analysis from the payer’s perspective. Weekly health state transition probabilities were derived retrospectively from results of a 12-week, randomized control trial (n=245) that compared the efficacy of Dermagraft plus conventional care in the treatment of DFUs to conventional care alone. Health states were verified by medical review and included healed, unhealed not infected, cellulitis, osteomyelitis and amputations. During weeks 1-8, Dermagraft could be used on a weekly basis for patients in the treatment group providing the ulcers were in an unhealed but not infected state. Amputee status was based on post-trial period patient follow-up for those who had adverse events. There were 6 (4.6%) ulcer-related amputations/resections among 130 patients in the Dermagraft plus conventional care arm, compared with 13 (11.3%) among 115 patients in the conventional care arm.

Diabetes is a chronic and disabling disease and the incidence is expected to grow significantly in the coming years due to an aging population and increasing trends towards obesity, unhealthy diets and sedentary lifestyles. The disease often leads to other health complications, such as heart disease, stroke and diabetic neuropathy, which can lead to DFUs. Of the chronic medical conditions that patients with diabetes are most likely to get, 15 to 25% will develop a DFU in their lifetime. Despite receiving good wound care, 70% of DFUs fail to heal within 20 weeks. The cost to treat a new DFU in the U.S. is estimated to be $51,531 in the first two years.

About Dermagraft

Dermagraft is a cryopreserved human fibroblast-derived dermal substitute; it is composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold. Dermagraft is manufactured from human fibroblast cells. During the manufacturing process, the human fibroblasts are seeded onto a bioabsorbable, polyglactin mesh scaffold. The fibroblasts proliferate to fill the interstices of this scaffold and secrete human dermal collagen, matrix proteins, growth factors, and cytokines to create a three-dimensional human dermal substitute containing metabolically active, living cells.

Dermagraft is indicated for use in the treatment of full-thickness DFUs greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Dermagraft should be used in conjunction with standard wound care regimens and in patients who have adequate blood supply to the involved foot. Clinical data from the pivotal study showed a 64% relative increase in wound closure for Dermagraft over active control in patients with diabetic foot ulcers of greater than 6 weeks duration and a similar incidence of reported adverse events for both treatment groups.

Source: Advanced BioHealing, Inc




Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Diabetes headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.

Medical Equipment Technology Advancing Rapidly

From ultrasound imaging on smartphones to robot surgeries, we found these incredible advancements in medical technology uncovered by articlesbase.com fascinating.

The ultrasound machine that fits in the palm of your hand

Ultrasound Imaging on Your Phone
Ultrasound machines are still relatively clunky and heavy. But with the help of a $100,000 grant from Microsoft, researchers at Washington University have created the first ever portable ultrasound machine that fits in the palm of your hand by combining the Microsoft smartphone with USB-based ultrasound probe technology. With the device patient data from remote locations can be sent to specialists via phone instantly, and they can in turn study the data and send back a diagnosis.

New Prostate Treatment: Cavitation
Treatment of prostate growths is traditionally invasive, painful and not always effective. At the University of Michigan in Ann Arbor, however, urologists have developed a new method of treating prostate growths by using highly focused microwave pulses. When these pulses reach the growth, they create bubbles of dissolved gas from prostate tissue. When these microscopic bubbles explode, they create a shockwave, which dissolves the growth. This shockwave effect is called cavitation, and not many thought that it could ever be controlled with such precision.

Microwaving Tumors
Liver cancer treatment involves either surgery or transplant.  But a third option is now available at the UC San Diego Medical Center. It’s called microwave ablationand it involves inserting a thin needle into the cancerous tumor and then emitting hot microwaves into it, causing it to die after about 10 minutes. The potential to use microwave ablation to treat other types of cancer is being studied.

Microwave ablation, a new minimally-invasive option for treating liver tumors

Gamma Cameras
High-res gamma cameras have become one of the most useful tools for the diagnosis of breast cancer. Other imaging techniques did not provide sufficient detail to fully detect cancer in some instances. Brest-specific gamma imaging (BSGI) is helping doctors detect cancer cases that would have otherwise remained overlooked.

Doctor-free Surgeries
Engineers at Duke University are working to bring about the advent of robot surgeries, unassisted by human hands. By using a rudimentary tabletop robot and 3D ultrasound imaging along with an artificial intelligence program, they built a robot that can perform basic surgical tasks on its own. Though far from practical yet, their robot marks one of the first steps towards this space age dream of someday having robots that perform all kinds of medical procedures, especially in places not immediately accessible to humans.

NRAS Very Disappointed With Negative NICE Announcement For Abatacept In Rheumatoid Arthritis (RA)

Main Category: Arthritis / Rheumatology
Article Date: 24 Jun 2011 – 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

NICE have issued a negative Final Appraisal Document (FAD) for abatacept, not recommending its use in patients with Rheumatoid Arthritis (RA) following treatment failure with DMARDs. The biologic treatments which have been licensed for use post DMARD failure are TNF antagonists, tocilizumab, already rejected for use by NICE, and abatacept, also now rejected by NICE. This means that patients who have failed on standard treatment (2 DMARDs including methotrexate) who are contra-indicated for anti-TNF, have had the only two remaining licensed biologic treatments for this point in the treatment pathway denied to them.

Abatacept is a selective T-cell modulator licensed for the treatment of moderate to severe RA in adults whose disease has responded inadequately to previous therapy with one or more DMARDs including methotrexate or a tumour necrosis factor (TNF) inhibitor.

NRAS is very disappointed because this decision by NICE will leave a group of patients with no biologic options after failure of two conventional DMARDs, following which pain and disability are likely to increase. The alternative treatment available to some would be rituximab, although this is less suitable for those with sero-negative disease and it is not licensed for use post DMARD failure or passed by NICE for use at this point in the patient pathway.

NRAS believes patients who could benefit from a clinically proven treatment should not be discriminated against on the grounds of health status.

Ailsa Bosworth, CEO of NRAS said “This is not good news for this group of patients. Asking them to continue on DMARDs when they have failed at least two including methotrexate and have a DAS score greater than 5.1 is condemning them to a life of pain and misery, with worsening disease which offers an ever decreasing quality of life. For these patients, long term, high dose steroids may become the only option, an option which is not recommended by NICE.”

Source:

National Rheumatoid Arthritis Society




Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Arthritis / Rheumatology headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.

AARP To Senators: Best Way To Hold Down Costs In Medicare Is To Hold Down Costs Throughout Health Care System

Main Category: Medicare / Medicaid / SCHIP
Article Date: 24 Jun 2011 – 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article


Patient / Public:not yet rated

Healthcare Prof:not yet rated

AARP this morning submitted a statement to the Senate Finance Committee as it discusses the future of health care entitlements. As Congress works to confront the nation’s finances, the Association urges lawmakers to consider proposals that would save money without making harmful cuts to vital Medicare and Medicaid benefits that provide a lifeline for millions of older Americans.

Excerpts of AARP’s statement follow:

“Older Americans overwhelmingly believe that Medicare and Social Security should be ‘off the table’ for deficit reduction. In fact, 78 percent believe that Congress should find ways to solve the nation’s deficit without making dangerous cuts to Medicare and Social Security.

On Medicare:

“Singling out the Medicare program – either for arbitrary cuts or for increased costs to beneficiaries – will not rein in overall health care costs. It will simply shift costs on to other payers of health care services, particularly beneficiaries and their families, and undermine current and future beneficiaries’ access to quality care.

“The best way to hold down costs in Medicare is to hold down costs throughout the health care system, with particular emphasis on delivery system reform.

“AARP encourages Congress to enact the longest possible resolution to the SGR problem. We believe any solution should aim to emphasize value over volume, and take steps to promote better quality care. Our members believe Congress has a responsibility to keep doctors in Medicare so today’s seniors and future retirees can keep seeing the doctors they trust.

On Medicaid:

“Medicaid is the nation’s largest payer for long-term care. Nearly a third of those turning age 65 will have long-term care costs that exceed their ability to pay and will need Medicaid assistance to help with LTC.

“As Congress considers proposals to reduce spending in Medicaid, we want to ensure that Congress understands the importance of the program to older Americans and their families. AARP is concerned that putting arbitrary caps on federal Medicaid spending could reduce access to and quality of care, such as reducing staffing in nursing homes, which could put the health and safety of seniors and people with disabilities at risk.

“Medicaid cuts could also reduce access to much needed, preferred, and cost effective home and community-based services. … And, on average, Medicaid can provide home and community-based services to three people for the cost of serving one person in a nursing home.

“Significant cuts to Medicaid cannot be made without harming individuals and families who rely on Medicaid for health or long-term services and supports, and these individuals include formerly middle income people who have had their life savings wiped out by the high costs of LTSS.

On examples of savings Congress should consider:

“Prescription Drug Rebates for Duals: AARP supports legislation (S. 1206) recently introduced by Senator Rockefeller and others that would require prescription drug manufacturers to provide rebates for drugs provided to Medicare Part D low-income subsidy beneficiaries, including those who are dually eligible for Medicare and Medicaid. This legislation is expected to save the Medicare program over $100 billion over the next ten years without negatively impacting Medicare Part D benefits.

“Medicare Secretarial Negotiating Authority: AARP supports legislation that builds upon the strong foundation of the Medicare prescription drug law by enabling the Secretary of HHS to use the bargaining power of Medicare’s 47 million beneficiaries to negotiate for lower prescription drug prices.

“Prescription Drug Reimportation: AARP supports the Pharmaceutical Market Access and Drug Safety Act, sponsored by Senators Stabenow and Snowe, which would establish a framework for the safe, legal importation of lower-priced prescription drugs from abroad.”

Source:

AARP




Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Medicare / Medicaid / SCHIP headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.

‘Simponi’® (golimumab) Receives Provisional Recommendation From NICE For The Treatment Of Ankylosing Spondylitis

Main Category: Arthritis / Rheumatology
Also Included In: Pain / Anesthetics;  Bones / Orthopedics
Article Date: 24 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

MSD today announced that the National Institute for Health and Clinical Excellence (NICE) has, in its final appraisal determination (FAD), provisionally recommended ‘Simponi’® (golimumab) as an option for the treatment of severe, active ankylosing spondylitis (AS) in adults.1 Use of golimumab, the first once-monthly, self-administered, subcutaneous anti-TNF (anti-tumour necrosis factor-alpha), is recommended only if it is used in the same way as other anti-TNFs and if MSD provides the 100mg dose at the same cost as the 50mg dose. The recommendation in this FAD is expected to be published as NICE final guidance over the coming months.

NICE also issued this week its final guidance (Technology Appraisal Guidance, TAG 225), recommending the use of golimumab for the treatment of moderate to severe rheumatoid arthritis (RA), in combination with methotrexate, in eligible adults.2

Professor Peter Taylor, Head of Clinical Trials and Campus Dean, Imperial College, London said: “These two positive NICE announcements acknowledge the clinical and economic rationale for the use of golimumab in RA and AS, which can be extremely painful and debilitating conditions that can impact on every area of life. Providing patients and their health care professionals with an additional treatment choice that can help improve patients’ well-being and quality of life is to be welcomed.”

AS is a painful and progressive rheumatic disease which mainly affects the spine and pelvis causing inflammation of joints, ligaments and tendons, which can lead to severe joint and back stiffness, deformity and immobility.3 It is estimated there are 4,400 new cases per 100,000 of AS diagnosed every year in the UK.4

Golimumab is licensed for use in three rheumatology indications: RA, AS and PsA, and shows consistent efficacy, significantly reducing the signs and symptoms of disease activity in these three diseases. Additionally, golimumab has also been found to improve physical function in patients.5,6,7 Upper respiratory tract infection (nasopharyngitis, pharyngitis, laryngitis and rhinitis) was the most frequent adverse reaction reported in combined phase 3 trials for RA, PsA and AS.8 The once-monthly dosing schedule of golimumab offers patients greater convenience compared with other currently available anti-TNFs and also offers a lower level of injection-site reaction.8


‘Simponi’® (golimumab)

Golimumab is licensed in the UK, having received marketing authorisation from the European Commission in late 2009. Other than in the EU, golimumab has also been approved for use in USA and Canada. The approved dose for golimumab is a 50 mg subcutaneous injection given once monthly either through the golimumab SmartJect™ auto injector or a prefilled syringe. ‘Simponi’ is a Registered Trademark owned by Centocor, Inc. and licensed to Merck and Co., Inc., Whitehouse Station, New Jersey, USA,


Licensed indications8

AS

Golimumab is indicated for the treatment of severe, active AS in adults who have responded inadequately to conventional therapy.

RA

Golimumab, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy, including MTX, has been inadequate. Golimumab, in combination with MTX, is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX. Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function in RA patients.

PsA

Alone or in combination with methotrexate, golimumab is indicated for the treatment of active and progressive PsA in adults when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.

Please refer to the Summary of Product Characteristics for full information on golimumab including contraindications, precautions, special warnings and side effect information. Available here.

About Ankylosing Spondylitis (AS)

AS is a painful and progressive rheumatic disease which mainly affects the spine and pelvis causing inflammation of joints, ligaments and tendons, which can lead to severe joint and back stiffness, deformity and immobility.3 Once the inflammation has subsided, the body, as part of its healing process, creates new bone. Movement becomes restricted where bone replaces the elastic tissue of ligaments or tendons. Repetition of this inflammatory process leads to further bone formation and the individual bones which make up your backbone, the vertebrae, can fuse together.3 It is estimated there are 4,400 new cases per 100,000 of AS diagnosed every year in the UK.4

About Rheumatoid Arthritis (RA)

RA is a chronic, debilitating inflammatory disease that causes swelling, stiffness, and loss of function in joints.9 RA is an autoimmune disease which occurs when the immune system attacks the body’s own healthy tissue and causes inflammation. RA usually affects the hands, feet and wrists, but can also spread to joints all over the body. Around 580,000 people in England have RA, with an estimated 26,000 new cases diagnosed each year.10 Onset usually begins in middle-age but the condition can also affect children and young adults.9

About Psoriatic Arthritis (PsA)

Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and connective tissue affecting up to 30% of individuals with psoriasis (a common skin disorder).11 Onset of PsA usually occurs in middle-age and can affect one or two joints, but can also affect several joints making them tender, swollen and stiff.11

About MSD

Today’s MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information, visit www.msd.com or www.msd-uk.co.uk.

References

1. NICE Final Appraisal Determination on golimumab for the treatment of severe, active ankylosing spondylitis. June 2011.

2. NICE Technology Appraisal Guidance TA225. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs. June 2011.

3. A Positive Response to Ankylosing Spondylitis: Answers and practical advice. Available at http://www.nass.co.uk/about-as/just-diagnosed/. Accessed on 11th April 2011.

4. Ankylosing spondylitis data. Available at: http://www.arthritisresearchuk.org/research/data_on_arthritis/data_on_as.aspx. Accessed on 11th April 2011.

5. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-796.

6. Kavanaugh A, McInnes I, Mease, P. et al. Golimumab, a new human tumor necrosis factor antibody,
administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheumatism 2009; 60(4): 976-986.

7. Inman RD, Davis JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis. Arthritis Rheumatism 2008; 58(11): 3402-3412.

8. Simponi Summary of Product Characteristics. June 2011. Available from: http://www.medicines.org.uk/emc/medicine/23766/SPC/simponi%2050%20mg%20solution%20for%20injection/ Accessed on 20th June 2011.

9. National Rheumatoid Arthritis Society (NRAS). What is RA? Available at: http://www.nras.org.uk/about_rheumatoid_arthritis/what_is_ra/what_is_ra.aspx. Accessed on 11th April 2011.

10. National Audit Office. Services for People with Rheumatoid Arthritis. Available from: http://www.nao.org.uk/publications/0809/services_for_people_with_rheum.aspx. Accessed on 11th April 2011.

11. National Psoriasis Foundation: Psoriatic Arthritis. Available from: http://www.psoriasis.org/NetCommunity/Document.Doc?id=912. Accessed on 11th April 2011.

Source
MSD




Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Arthritis / Rheumatology headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.